Preoperative Antiviral Therapy and Long-Term Outcomes for Hepatitis B Virus-Related Hepatocellular Carcinoma After Curative Liver Resection: A Multicenter Analysis
Mu-Gen Dai,Si-Yu Liu,Lin Zhu,Wen-Feng Lu,Gui-Lin Xie,Lei Liang,Jun-Wei Liu,Bin Ye
DOI: https://doi.org/10.2147/jhc.s457135
2024-05-24
Journal of Hepatocellular Carcinoma
Abstract:Mu-Gen Dai, 1, 2 Si-Yu Liu, 2 Lin Zhu, 3 Wen-Feng Lu, 4 Gui-Lin Xie, 5 Lei Liang, 6 Jun-Wei Liu, 6 Bin Ye 1 1 Department of Gastroenterology, The Fifth Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, People's Republic of China; 2 Department of Laboratory Medicine, The Key Laboratory of Imaging Diagnosis and Minimally Invasive Interventional Research of Zhejiang Province, Zhejiang University Lishui Hospital, Lishui, Zhejiang, People's Republic of China; 3 Department of Gastroenterology, Wenzhou Medical University, Wenzhou, Zhejiang Province, People's Republic of China; 4 Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, People's Republic of China; 5 Department of Hepatobiliary Surgery, Affiliated Hospital of Shaoxing University, Shaoxing, Zhejiang Province, 312000, People's Republic of China; 6 General Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China Correspondence: Jun-Wei Liu, General Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China, Email Bin Ye, Department of Gastroenterology, The Fifth Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, People's Republic of China, Email Background & Aims: To examine the association of the history of preoperative antiviral therapy (AVT) with the tumor recurrence and overall survival in HBV-related HCC patients undergoing curative-intent hepatectomy. Methods: Patients who underwent curative-intent hepatectomy for HBV-related HCC between 2014 and 2019 at 4 Chinese hospitals were analyzed. Patients were categorized as having undergone preoperative antiviral therapy (AVT) > 1 year or without antiviral therapy (non-AVT). Patient clinical features, short-term outcomes, overall survival (OS), and time-to-recurrence (TTR) were also compared. Multivariate Cox regression analysis was performed to identify the impact of preoperative AVT on the OS and TTR. Results: Among the 565 patients, 190 (33.6%) underwent continuous AVT > 1 year before surgery. Patients in the non-AVT group were more likely to have worse liver function and more advanced tumor pathological characteristics than those in the AVT group. Postoperative morbidity and mortality rates were comparable between the two groups. Multivariate analyses revealed that a preoperative HBV viral level ≥ 2000 IU/mL was independently associated with poorer TTR (hazard ratio, 1.328; 95% CI, 1.049– 1.682) and preoperative AVT was a protective factor for OS (hazard ratio, 0.691; 95% CI, 0.484– 0.986). Conclusion: A high preoperative HBV DNA level was an independent risk factor for tumor recurrence. Preoperative AVT > 1 year was associated with better OS and a reduced incidence of tumor recurrence by inhibiting the preoperative level of HBV DNA. Keywords: hepatectomy, hepatitis B virus, antiviral therapy, survival, recurrence Graphical Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and ranks as the fifth most prevalent tumor and second leading cause of cancer-related deaths worldwide. 1 Partial liver resection remains as the mainstay of curative modality used to treat HCC in appropriately selected patients. 2,3 Owing to the high recurrence and mortality rates of HCC, long-term prognosis outcomes remain unsatisfactory, despite patients undergoing radical treatment. Hepatitis B virus (HBV) infection is a significant risk factor for HCC, and China has the highest prevalence of HCC cases associated with HBV. 4,5 However, a host of HCC patients commonly only become aware of their HBV infection when they seek medical attention because of symptoms caused by advanced tumors. 6,7 Previous studies have shown that long-term antiviral therapy (AVT) with nucleoside analogs (NAs) can reduce the incidence of HCC and prolong the survival of patients with chronic HBV infection. 8–11 A high preoperative HBV load is associated with postoperative recurrence. 12–14 Antiviral treatment after surgery for HBV-related HCC can reduce tumor recurrence and is widely used in clinical practice. 15–17 Preoperative short-term AVT has been reported to re -Abstract Truncated-
oncology